Gordon Orr joins Nick Leung and Joe Ngai for a conversation on what lies ahead for China in 2017.

What are the real forces driving the market for cross-border M&A?

Homegrown companies are driving China's biopharma sector to new levels of innovation and growth.

The battle between fintech attackers and incumbent financial institutions in China heats up

Despite a cooling auto market in China, there are several promising areas of growth.

Chinese consumers remain surprisingly confident, and are spending more on products and services that are aimed at enhancing the quality of their lives.

There is growing concern that the high levels of debt tied to the real estate sector could be a source of instability.

Despite the recent negative economic headlines coming out of China, some private equity investors are taking a more positive view.

China's latest GDP growth figure intensified the debate around the state of the economy.

2015 has been an eventful year for China. The economy cooled. The stock market took a hit. But what’s in store for China in 2016?

Access to quality drugs is becoming a critical issue in China’s journey toward modernizing its healthcare system.

Big data is beginning to have big impact in China, but in what areas and to what extent?

A discussion on the economic implications of the lack of parity between men and women in China.

The question is no longer will China innovate, but how and where.